Header Logo

Connection

JACOB MANDEL to Glioblastoma

Back to Details
This is a "connection" page, showing publications JACOB MANDEL has written about Glioblastoma.
JACOB MANDEL
Connection Strength
4.550
Glioblastoma
  1. External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma. JAMA Oncol. 2023 07 01; 9(7):1006.
    View in: PubMed
    Score: 0.619
  2. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas. Neurosurg Focus. 2022 12; 53(6):E16.
    View in: PubMed
    Score: 0.595
  3. Effect of health disparities on overall survival of patients with glioblastoma. J Neurooncol. 2019 Apr; 142(2):365-374.
    View in: PubMed
    Score: 0.455
  4. Highlighting the need for reliable clinical trials in glioblastoma. Expert Rev Anticancer Ther. 2018 10; 18(10):1031-1040.
    View in: PubMed
    Score: 0.439
  5. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018 01 10; 20(1):113-122.
    View in: PubMed
    Score: 0.424
  6. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol. 2016 08; 129(1):147-54.
    View in: PubMed
    Score: 0.379
  7. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. J Neurooncol. 2014 Dec; 120(3):597-605.
    View in: PubMed
    Score: 0.336
  8. Discontiguous recurrences of IDH-wildtype glioblastoma share a common origin with the initial tumor and are frequently hypermutated. Acta Neuropathol Commun. 2025 01 16; 13(1):9.
    View in: PubMed
    Score: 0.172
  9. Federated learning enables big data for rare cancer boundary detection. Nat Commun. 2022 12 05; 13(1):7346.
    View in: PubMed
    Score: 0.149
  10. The concurrence of multiple sclerosis and glioblastoma. Mult Scler Relat Disord. 2021 May; 50:102877.
    View in: PubMed
    Score: 0.132
  11. Multicentric non-enhancing lesions in glioblastoma: A retrospective study. J Clin Neurosci. 2021 Mar; 85:20-26.
    View in: PubMed
    Score: 0.130
  12. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
    View in: PubMed
    Score: 0.124
  13. Treatment strategies for glioblastoma in older patients: age is just a number. J Neurooncol. 2019 Nov; 145(2):357-364.
    View in: PubMed
    Score: 0.120
  14. Disparities along the glioblastoma clinical trials landscape. Neuro Oncol. 2019 02 14; 21(2):285-286.
    View in: PubMed
    Score: 0.114
  15. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. J Neurooncol. 2017 Oct; 135(1):75-81.
    View in: PubMed
    Score: 0.102
  16. Wound healing complications in brain tumor patients on Bevacizumab. J Neurooncol. 2015 Sep; 124(3):501-6.
    View in: PubMed
    Score: 0.090
  17. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol. 2015 Aug; 124(1):87-94.
    View in: PubMed
    Score: 0.088
  18. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol. 2014 Aug; 119(1):135-40.
    View in: PubMed
    Score: 0.082
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.